#United Kingdom #ADC #Piramal Pharma #Grangemouth

Piramal Pharma Solutions Achieves a Major Milestone

In a notable achievement for the pharmaceutical industry, Piramal Pharma Solutions, a recognized leader in Contract Development and Manufacturing Organization (CDMO) services, has proudly announced the successful delivery of its 1,500th batch of antibody-drug conjugates (ADCs) from its state-of-the-art facility located in Grangemouth, Scotland. This milestone emphasizes not only the operational efficiency of the plant but also Piramal's commitment to providing crucial bioconjugate therapies to patients in need.

For over two decades, Piramal Pharma Solutions has maintained its position at the forefront of ADC development and manufacturing. As the first FDA-approved CDMO in this domain, the company has pioneered the commercial production of ADCs. This unique expertise has enabled Piramal to offer an integrated suite of ADC solutions from Grangemouth, ranging from proof-of-concept studies to large-scale clinical and commercial manufacturing. This capacity solidifies Grangemouth's role as a critical component of Piramal's ADCelerate™ program—an accelerated, integrated Phase I ADC initiative. Supported by robust program management, engineering, and quality teams, the program ensures a seamless technology transition, effectively streamlining the journey from research and development to GMP-compliant production.

The Grangemouth facility has successfully brought to life hundreds of unique bioconjugates, producing not only commercial ADC batches but also clinical and non-GMP batches. This is complemented by the site’s talented professionals from the Science Collective, whose technical expertise plays a significant role in driving project success. Upholding its commitment to quality, Grangemouth boasts an impressive track record in regulatory approvals, having received accreditations from both the FDA and the MHRA.